Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
Sponsor: White River Junction Veterans Affairs Medical Center
Summary
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Official title: Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder
Key Details
Gender
All
Age Range
19 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
92
Start Date
2023-12-18
Completion Date
2026-09-30
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
Glecaprevir/pibrentasvir
Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
Placebo
Compounded, inactive pill equal in appearance to active study drug
Locations (1)
White River Junction VAMC
White River Junction, Vermont, United States